Jens Fleckenstein

Jens Fleckenstein

Auto-generated profile, based on publicly available information

Jens Fleckenstein

Department of Radiation Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JTJohannes Thoelking
Johannes Thoelking
JFJens Fleckenstein
Jens Fleckenstein
YSYuvaraj Sekar
Yuvaraj Sekar
RBRamesh Boggula
Ramesh Boggula
FLFrank Lohr
Frank Lohr
HWHansjoerg Wertz
Hansjoerg Wertz

1 September 2012 in Zeitschrift für Medizinische Physik
Verified
Journal Article
Open access
SCSven Clausen
Sven Clausen
FSFrank Schneider
Frank Schneider
LJLennart Jahnke
Lennart Jahnke
JFJens Fleckenstein
Jens Fleckenstein
JHJürgen Hesser
Jürgen Hesser
FWFrederik Wenz
Frederik Wenz
To generate and validate a source model of a miniature X-ray generator (INTRABEAM, Carl Zeiss Surgical, Oberkochen, Germany) for endovaginal TARGeted Intra-operative radioTherapy (TARGIT) brachytherapy a Geant4-based Monte Carlo (MC) tool was developed. The model was used to calculate the accurate relative dose distribution for the source combined with a cylindrical applicator which was developed for endovaginal treatment. Geometries with given materials of the X-ray source and applicator were implemented in a Geant4-based dose calculation framework. To reduce the calculation time, phase space files for a set of circular electron beam foci and different beam radii were precalculated. Different beam radii had to be considered because the exact electron beam path on the target is not known in advance. To estimate the electron beam radius distribution of the system, a least squares minimization between the EBT film measured relative dose distribution and the simulation was performed. Relative dose distributions were calculated and compared with Gafchromic EBT film measurements to validate the MC method. In a region of interest around the source, the 2%/2mm gamma criterion matched with 98%. Profiles showed excellent agreement between measurement and simulation. The calculation time to simulate an entire treatment was twelve minutes. The method was able to predict the radius and width of the trajectory where the electrons impact on the target. This enables the complete simulation. The developed method allows calculating relative dose distributions for endovaginal TARGIT brachytherapy matching measured relative dose distributions within clinically acceptable limits.

19 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MFManuela C. Felix
Manuela C. Felix
JFJens Fleckenstein
Jens Fleckenstein
SKStefanie Kirschner
Stefanie Kirschner
LHLinda Hartmann
Linda Hartmann
FWFrederik Wenz
Frederik Wenz
FGFrank A. Giordano
Frank A. Giordano
Although radiotherapy is a key component of cancer treatment, its implementation into pre-clinical in vivo models with relatively small target volumes is frequently omitted either due to technical complexity or expected side effects hampering long-term observational studies. We here demonstrate how an affordable industrial micro-CT can be converted into a small animal IGRT device at very low costs. We also demonstrate the proof of principle for the case of partial brain irradiation of mice carrying orthotopic glioblastoma implants. A commercially available micro-CT originally designed for non-destructive material analysis was used. It consists of a CNC manipulator, a transmission X-ray tube (10–160 kV) and a flat-panel detector, which was used together with custom-made steel collimators (1–5 mm aperture size). For radiation field characterization, an ionization chamber, water-equivalent slab phantoms and radiochromic films were used. A treatment planning tool was implemented using a C++ application. For proof of principle, NOD/SCID/γc−/− mice were orthotopically implanted with U87MG high-grade glioma cells and irradiated using the novel setup. The overall symmetry of the radiation field at 150 kV was 1.04±0.02%. The flatness was 4.99±0.63% and the penumbra widths were between 0.14 mm and 0.51 mm. The full width at half maximum (FWHM) ranged from 1.97 to 9.99 mm depending on the collimator aperture size. The dose depth curve along the central axis followed a typical shape of keV photons. Dose rates measured were 10.7 mGy/s in 1 mm and 7.6 mGy/s in 5 mm depth (5 mm collimator aperture size). Treatment of mice with a single dose of 10 Gy was tolerated well and resulted in central tumor necrosis consistent with therapeutic efficacy. A conventional industrial micro-CT can be easily modified to allow effective small animal IGRT even of critical target volumes such as the brain.

28 February 2013 in Zeitschrift für Medizinische Physik
Verified
Journal Article
Open access
JFJens Fleckenstein
Jens Fleckenstein
LJLennart Jahnke
Lennart Jahnke
FLFrank Lohr
Frank Lohr
FWFrederik Wenz
Frederik Wenz
JHJürgen Hesser
Jürgen Hesser
A method to evaluate the dosimetric accuracy of volumetric modulated arc therapy (VMAT) treatment plans, generated with the MONACOTM (version 3.0) treatment planning system in realistic CT-data with an independent Geant4 based dose calculation algorithm is presented. Therefore a model of an Elekta Synergy linear accelerator treatment head with an MLCi2 multileaf collimator was implemented in Geant4. The time dependent linear accelerator components were modeled by importing either logfiles of an actual plan delivery or a DICOM-RT plan sequence. Absolute dose calibration, depending on a reference measurement, was applied. The MONACO as well as the Geant4 treatment head model was commissioned with lateral profiles and depth dose curves of square fields in water and with film measurements in inhomogeneous phantoms. A VMAT treatment plan for a patient with a thoracic tumor and a VMAT treatment plan of a patient, who received treatment in the thoracic spine region including metallic implants, were used for evaluation. MONACO, as well as Geant4, depth dose curves and lateral profiles of square fields had a mean local gamma (2%, 2 mm) tolerance criteria agreement of more than 95% for all fields. Film measurements in inhomogeneous phantoms with a global gamma of (3%, 3 mm) showed a pass rate above 95% in all voxels receiving more than 25% of the maximum dose. A dose-volume-histogram comparison of the VMAT patient treatment plans showed mean deviations between Geant4 and MONACO of -0.2% (first patient) and 2.0% (second patient) for the PTVs and (0.5 ± 1.0)% and (1.4 ± 1.1)% for the organs at risk in relation to the prescription dose. The presented method can be used to validate VMAT dose distributions generated by a large number of small segments in regions with high electron density gradients. The MONACO dose distributions showed good agreement with Geant4 and film measurements within the simulation and measurement errors. Eine Methode zur Evaluierung der dosimetrischen Genauigkeit von MONACO™ (Version 3.0)-VMAT-Behandlungsplänen in realen CT-Datensätzen mittels eines unabhängigen, auf Geant4 basierten Monte-Carlo-Dosisberechnungsalgorithmus wird vorgestellt. Hierfür wurde ein Modell eines Elekta-Synergy-Linearbeschleunigers mit MLCi2-Kollimator in Geant4 implementiert. Um die zeitlich veränderlichen Komponenten des Beschleunigerkopfes zu modellieren, wurden entweder logfiles einer Bestrahlung oder DICOM-RT-Pläne importiert. Ein auf einer Referenzmessung beruhender Formalismus zur Kalibration der absoluten Dosis wurde angewandt. Sowohl die MONACO- als auch die Geant4-Simulationen wurden mit lateralen Profilen und Tiefendosiskurven quadratischer Feldgeometrien in Wasser und mit Film-Messungen in inhomogenen Phantomen validiert. Ein Vergleich zwischen MONACO- und Geant4-generierten Dosisverteilungen wurde für einen VMAT-Bestrahlungsplan eines Patienten mit einem thorakalen Tumor sowie einen Bestrahlungsplan eines Patienten, der in der Wirbelsäulen-Region in Gegenwart metallischer Implantate bestrahlt wurde, durchgeführt. Sowohl MONACO als auch Geant4 zeigten für die Tiefendosiskurven und die lateralen Profile der quadratischen Felder bei einem lokalen Gamma (2%, 2 mm) Kriterium für alle Felder eine mittlere Übereinstimmung von mehr als 95%. Filmmessungen in inhomogenen Phantomen erfüllten ein globales Gamma (3%, 3 mm) Toleranzkriterium in mehr als 95% aller Voxel, die mehr als 25% der Maximaldosis erhielten. Die Dosis-Volumen-Histogramme der beiden VMAT-Behandlungen zeigten Unterschiede in der mittleren Dosis im Zielvolumen zwischen Geant4 und MONACO von -0,2% im ersten und 2,0% im zweiten Fall. Die Risikoorgane zeigten dosimetrische Unterschiede von (0,5 ± 1,0)% und (1,4 ± 1,1)% bezogen auf die Verschreibungsdosis. Die vorgestellte Methode kann verwendet werden, um VMAT-Dosisverteilungen, die durch viele kleine Segmente generiert wurden, in Regionen mit großen Elektronendichtevariationen zu verifizieren. Die mit MONACO simulierten Dosisverteilungen zeigten innerhalb der Fehler eine gute Übereinstimmung mit Geant4 sowie den Filmmessungen.

30 July 2018 in Anticancer Research
Verified
Journal Article
Open access
PDF file
DBDaniel Buergy
Daniel Buergy
LRLeonie Rabe
Leonie Rabe
KSKerstin Siebenlist
Kerstin Siebenlist
FSFlorian Stieler
Florian Stieler
JFJens Fleckenstein
Jens Fleckenstein
JBJudit Boda-Heggemann
Judit Boda-Heggemann
Background/Aim: Metastases involving the adrenal glands can be treated surgically or with radiation therapy. Retrospective studies indicate that radiotherapy for this indication is safe, well-tolerated and associated with symptom palliation and good local control. We conducted this analysis to report on patterns and outcomes of patients with adrenal metastases treated with hypo- or conventionally fractionated image-guided radiotherapy. Patients and Methods: Patients with adrenal metastases from solid tumors treated at our department between 01/2010-12/2017 were reviewed. A total of 22 lesions were treated in 18 patients with a median dose of 35 Gy (20-60 Gy) in a median number of 7 (4-25) fractions. Results: No grade ≥3 toxicity occurred. Median overall survival was 11.9 months. Five local failures occurred (22.7%). Lesion sizes or radiation dose were not correlated with local control. Patients treated for oligometastatic and oligoprogressive disease had a median overall survival of 33 and 6.5 months, respectively (palliative/polymetastatic: 1.6 months). Symptoms improved in all patients treated for clinically apparent lesions. Conclusion: Stereotactic radiotherapy of adrenal metastases was safe and effective in patients with oligometastases or oligoprogression. In palliative patients, short-course radiotherapy complemented with supportive care should be preferred.

25 May 2018 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
JFJens Fleckenstein
Jens Fleckenstein
JBJudit Boda-Heggemann
Judit Boda-Heggemann
KSKerstin Siebenlist
Kerstin Siebenlist
TGTanya Gudzheva
Tanya Gudzheva
NPNatallia Prakofyeva
Natallia Prakofyeva
ASAnna Simeonova-Chergou
Anna Simeonova-Chergou